Nooshin Hashemi Sadraei

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Journal of Clinical Oncology · 2023 · 288 citations

Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Cancer Research · 2023 · 62 citations